NIPRO CORPORATION FY2027 Q1 Earnings Report

Quick View

Executive Summary

Although revenue and earnings increased in Q1, the operating margin remains low, leaving substantial room for improvement in the earnings structure. Revenue was ¥1675.5B (+5.2% YoY), operating income was ¥77.1B (+6.9%), ordinary income was ¥66.1B (+87.8%), and net income attributable to owners of the parent was ¥38.4B (+17.4%). Revenue growth was driven by expansion in the Medical-Related and Pharma Packaging businesses; however, the core Medical-Related segment posted lower profit, while the significant increase in ordinary income was temporarily boosted by foreign exchange gains and extraordinary income, including government subsidies.

Factors Affecting Performance

【Revenue】Revenue increased 5.2% YoY to ¥1675.5B. By segment, the Medical-Related business was the largest at ¥1120.7B (66.9% of total, +6.2% YoY), followed by the Pharmaceutical-Related business at ¥407.1B (+1.9%) and Pharma Packaging at ¥169.8B (+8.8%). Strong growth in Pharma Packaging and solid revenue growth in the Medical-Related business supported the top line.

【Profit and Loss】Operating income increased 6.9% YoY to ¥77.1B. The gross margin improved from the previous year to 32.2%, but the SG&A expense ratio rose to 27.6%, partially offsetting the benefit of higher earnings. Segment profit declined in both of the two core businesses: Medical-Related was ¥98.5B (-4.5% YoY), and Pharmaceutical-Related was ¥37.4B (-6.9%). Pharma Packaging also remained a low-margin business, with a profit margin of 0.8%. Ordinary income increased 87.8% YoY to ¥66.1B, aided by foreign exchange gains of ¥17.3B, while interest expenses of ¥29.7B represented a significant burden and the overall non-operating burden remained substantial. Extraordinary income of ¥12.9B, including government subsidies, supported net income. Although revenue increased, segment profitability deteriorated; thus, while the results show higher revenue and earnings, they also contain elements more characteristic of higher revenue but lower underlying profitability.

Segment Analysis

The Medical-Related business posted revenue of ¥1120.7B (+6.2% YoY), operating income of ¥98.5B (-4.5%), and an 8.8% profit margin, resulting in higher revenue but lower earnings. The Pharmaceutical-Related business recorded revenue of ¥407.1B (+1.9%), operating income of ¥37.4B (-6.9%), and a 9.2% profit margin, also resulting in higher revenue but lower earnings. Pharma Packaging recorded revenue of ¥169.8B (+8.8%), operating income of ¥1.4B (-4.1%), and a profit margin of 0.8%, continuing to operate on a low-margin basis. Other businesses recorded revenue of ¥76.1B (-12.1%) and operating income of ¥0.2B (-86.7%), representing a substantial decline in earnings. Both core segments recorded higher revenue but lower earnings, which was the primary factor behind the lack of growth in the company-wide profit margin. It should also be noted that, beginning in Q1, changes to the depreciation method for property, plant and equipment boosted segment profit by ¥6.6B in Medical-Related, ¥3.5B in Pharmaceutical-Related, and ¥0.7B in Pharma Packaging.

Key Financial Metrics

【Profitability】The operating margin was 4.6%, while the net profit margin attributable to owners of the parent was 2.3%. Against a gross margin of 32.2%, the SG&A expense ratio increased to 27.6%, offsetting the benefit of gross margin improvement.【Cash Flow Quality】The significant increase in ordinary income was heavily supported by foreign exchange gains of ¥17.3B and extraordinary income of ¥12.9B, including government subsidies. Growth in core earnings was limited to a 6.9% increase in operating income.【Investment Efficiency】ROE was 1.4%. Interest expenses of ¥29.7B represented a significant burden against pretax income of ¥69.6B, indicating substantial room for improvement in capital efficiency.【Financial Soundness】The equity ratio was 28.2%, improving from 26.4% in the previous year (based on actual net assets/total assets). Although interest-bearing debt remained high, including long-term borrowings of ¥2687.3B and bonds of ¥1032.8B, treasury stock decreased to ¥67.1B, contributing to a substantial strengthening of capital.

Cash Flow Analysis

As the statement of cash flows has not been disclosed, funding trends are analyzed based on changes in the balance sheet. Cash and deposits totaled ¥1048.6B, increasing from ¥978.4B in the same period of the previous year, indicating a modest improvement in financial flexibility. Meanwhile, inventories remained high at ¥1815.0B, comprising finished goods inventories of ¥1815.0B, raw materials of ¥612.7B, and work in process of ¥261.8B. These elevated balances may be exerting pressure on working capital. Accounts receivable and notes receivable totaled ¥1724.8B, slightly declining from ¥1757.4B in the previous year, indicating an improving collection trend. Property, plant and equipment was largely unchanged at ¥5033.3B, suggesting that major investments were limited. Overall, the high inventory level remains a key area to monitor from a cash generation perspective.

Quality of Earnings

While operating income of ¥77.1B indicates recurring earnings power, the composition of ordinary income of ¥66.1B included non-operating income of ¥32.2B, including foreign exchange gains of ¥17.3B and dividend income of ¥0.9B, and non-operating expenses of ¥43.3B, including interest expenses of ¥29.7B. These items were broadly balanced, while reliance on foreign exchange, a highly non-recurring factor, was equivalent to approximately 22% of operating income. Extraordinary gains and losses amounted to a net gain of ¥3.5B, consisting mainly of government subsidies and other items within extraordinary income of ¥12.9B, while extraordinary losses of ¥9.4B included losses on disposal of fixed assets. These items temporarily boosted net income. In addition, changes to the depreciation method increased total segment profit by approximately ¥11.5B, meaning that part of the apparent improvement in earnings resulted from a non-recurring accounting factor. Comprehensive income was ¥88.4B, of which ¥77.4B was attributable to owners of the parent. The difference from net income of ¥38.4B was attributable to OCI items, including foreign currency translation adjustments of ¥37.3B, and should be viewed separately from the business’s recurring earnings power.

Earnings Forecast and Guidance

Progress against the full-year plan was 23.9% for revenue (¥1675.5B/¥7000.0B), 19.3% for operating income (¥77.1B/¥400.0B), and 24.1% for ordinary income (¥66.1B/¥274.0B). Operating income progress was below the standard 25% level. While revenue is progressing generally as planned, the delay in operating income appears to reflect deteriorating profitability in the core Medical-Related and Pharmaceutical-Related businesses, as well as the upfront burden of SG&A expenses. Ordinary income is progressing relatively well due to contributions from foreign exchange gains and extraordinary income. The company made no revisions to its earnings or dividend forecasts during the quarter.

Shareholder Returns

The full-year dividend forecast is ¥32.00 per share, representing an increase from the previous year’s interim dividend of ¥10. Based on the previous year’s actual dividend of ¥10 per share, an annual dividend increase is planned. Assuming full-year forecast net income attributable to owners of the parent of ¥150.0B and average shares outstanding during the period of 163,557 thousand shares, the payout ratio is approximately 35%. Treasury stock decreased to ¥67.1B from ¥107.5B in the previous year, indicating progress toward improving capital efficiency through a reduction in the number of shares outstanding.

Risk Factors

1. Concentration of Revenue in Core Segments: The Medical-Related business accounts for 66.9% of total revenue, while operating income in this segment declined 4.5% YoY. The high level of concentration could become a source of volatility in company-wide earnings.

2. Interest Burden and Interest-Bearing Debt: Interest expenses were ¥29.7B, while interest-bearing debt remained high, including long-term borrowings of ¥2687.3B and bonds of ¥1032.8B. Non-operating expenses continue to exceed non-operating income, resulting in high sensitivity to changes in interest rates.

3. Inventory Levels and Working Capital: Inventories totaled ¥1815.0B, with finished goods inventories accounting for the majority. Stagnant inventory requires monitoring from both a funding efficiency and obsolescence-risk perspective.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the operating margin and net profit margin are below the industry median, indicating that profitability is relatively low within the industry.

Growth and Capital Efficiency

The revenue growth rate is slightly below the industry median but remains within the IQR, indicating that growth is generally in line with industry-average levels.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. Although revenue increased, both the core Medical-Related and Pharmaceutical-Related segments recorded lower earnings. The gap between top-line growth and bottom-line improvement is a defining feature of the results.

2. The significant increase in ordinary income (+87.8%) was largely attributable to foreign exchange gains and extraordinary income, including government subsidies. In addition, changes to the depreciation method boosted segment profit by approximately ¥11.5B. These temporary and accounting-related factors must therefore be separated when assessing the underlying strength of core earnings.

3. Operating income progress against the full-year plan was 19.3%, below the standard progress level of 25%. Progress in absorbing costs and improving profitability in the second half will be closely watched as a prerequisite for achieving the plan.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,763–¥1,866 for a ±1% change in the cost of equity, and ¥1,805–¥1,819 for a change of ±0.1 in ω.

Notes:

• Net income is significantly compressed relative to operating income due to tax burdens, acquisition-related expenses, and non-controlling interests (net income ÷ operating income 38%). This value reflects that compression at face value; if these factors are temporary, the underlying value may be higher.
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Valuation model: Residual Income Model (Ohlson type; explicit 5-year fade) / Interest Rate Reference Month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---